Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Maxygen, Inc. (NasdaqNM:MAXY)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 14Earnings Announcement
Location
515 Galveston Drive
Redwood City, CA 94063
Phone: (650) 298-5300
Fax: (650) 364-2715
Employees (last reported count): 256
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 52%
·Over the last 6 months:
 · 2 insider sells; 8,000  shares
·Institutional: 16% (33% of float)
(132 institutions)
·Net Inst. Buying: 810.0K shares (+13.04%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Maxygen, Inc. is focused on using its integrated technologies to create novel therapeutic and industrial products for the field of directed molecular evolution, the process by which genes are modified for specific commercial uses. The Company's technologies bring together advances in molecular biology and protein modification to create biotechnology products. At December 31, 2000, the Company was working on over 40 different potential products, including eight potential products that are in the development stage. Maxygen's products will be developed and marketed either through corporate collaborations or independently by the Company. The Company's target markets include protein pharmaceuticals, preventative and therapeutic vaccines, chemicals and agriculture.
More from Market Guide: Expanded Business Description

Financial Summary
Maxygen, Inc. in engaged in the field of directed molecular evolution, utilizing the Company's proprietary technologies to mimic the natural process of evolution and bring together advances in molecular biology and classical breeding. For the six months ended 6/30/01, revenues rose 26% to $14.6 million. Net loss totaled $22.6 million, up from $10 million. Results reflect increased amounts earned under collaborative R&D agreements, offset by increased R&D costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Compensation
PayExer

Isaac Stein, 53
Chairman
--  --  
Russell Howard, Ph.D., 49
CEO, Director
$226K$33.8K
Simba Gill, Ph.D., 35
Pres
195K1.6K
Lawrence Briscoe
CFO, Sr. VP
--  --  
John Curd, M.D.
Sr. VP, Clinical Devel.
--  --  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:MAXYAs of 31-Aug-2001
Price and Volume
52-Week Low
on 29-Mar-2001
$9.75 
Recent Price$14.99 
52-Week High
on 29-Sep-2000
$56.625
Daily Volume (3-month avg)73.2K
Daily Volume (10-day avg)56.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-71.9%
52-Week Change
relative to S&P500
-62.3%
Share-Related Items
Market Capitalization$508.1M
Shares Outstanding33.9M
Float16.3M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$7.90 
Earnings (ttm)-$2.28 
Earnings (mrq)-$0.35 
Sales (ttm)$0.86 
Cash (mrq)$5.24 
Valuation Ratios
Price/Book (mrq)1.90 
Price/EarningsN/A 
Price/Sales (ttm)17.42 
Income Statements
Sales (ttm)$27.5M
EBITDA (ttm)-$62.7M
Income available to common (ttm)-$72.2M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-24.11%
Return on Equity (ttm)-25.82%
Financial Strength
Current Ratio (mrq)8.96 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$177.4M
Short Interest
As of 8-Aug-2001
Shares Short302.0K
Percent of Float1.9%
Shares Short
(Prior Month)
422.0K
Short Ratio5.03 
Daily Volume60.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.